WVE
T3Wave Life Sciences Ltd.
Loading chart…
OverviewWave Life Sciences is a clinical-stage biotechnology company developing RNA medicines using its PRISM platform. They focus on RNAi for obesity (WVE-007) and RNA
Wave Life Sciences is a clinical-stage biotechnology company developing RNA medicines using its PRISM platform. They focus on RNAi for obesity (WVE-007) and RNA editing for Alpha-1 antitrypsin deficiency (WVE-006) and liver diseases (WVE-008). The company's revenue primarily comes from strategic collaborations, such as with GSK. They aim to deliver scientific breakthroughs for rare and prevalent disorders to patients.
Search Keywords Brand Product
- WVE-007
- WVE-006
- WVE-008
- WVE-N531
- WVE-003
- PRISM platform
- SpiNA siRNA
- AIMers RNA editing
- RNA medicines
- RNAi therapy
- RNA editing
- obesity treatment
- alpha-1 antitrypsin deficiency
- AATD
- PNPLA3 liver disease
- Duchenne muscular dystrophy
- Huntington's disease
- genetic insights
- cardiometabolic diseases
- fat loss
- muscle preservation
Search Keywords Event Phrases
- Wave Life Sciences earnings
- WVE-007 Phase IIa data
- WVE-006 FDA meeting
Search Keywords Policy Regulatory
- accelerated approval pathway
- FDA regulatory feedback
- What They Do (Plain English & Analogies)
- Wave Life Sciences creates specialized medicines that work by targeting the body's genetic instructions. Imagine DNA as the master blueprint for building everything in your body, and RNA as the temporary instruction manuals copied from that blueprint to make specific parts or proteins. Wave's medicines are like tiny, precise 'editors' or 'silencers' for these instruction manuals. They can either fix mistakes in the RNA (a process called RNA editing) so the body makes the correct, healthy proteins, or they can 'turn off' faulty instructions (called RNA interference or RNAi) that lead to harmful proteins or processes. For example, for obesity, they are developing a medicine (WVE-007) that aims to 'turn off' a signal that tells fat cells to hold onto fat, essentially 'removing the brakes' on fat burning while preserving muscle. For genetic diseases, they are correcting specific faulty instructions that cause the illness.
- Very Brief History
- Wave Life Sciences Ltd. was founded in 2012 in Singapore. Over the past decade, the company has evolved into a clinical-stage biotechnology company focused on developing novel stereopure oligonucleotides through its proprietary PRISM discovery and drug development platform. It has established collaborations with major pharmaceutical companies, including GlaxoSmithKline (GSK) and previously Takeda Pharmaceutical Company Limited (which terminated) and Pfizer Inc. In August 2026, the company completed a redomiciliation process, changing its parent company from a Singapore entity to Wave Life Sciences, Inc., a Delaware corporation, and is headquartered in Cambridge, MA.
- "Street Stereotype"
- Wave Life Sciences is generally perceived as an innovative, early-stage platform company in the advanced biotechnology and regenerative medicine space. While it holds compelling intellectual property and partnerships, it has historically faced challenges related to cash burn and investor apathy often associated with small-cap, preclinical/early-clinical stage companies. However, recent positive clinical data, particularly in obesity and Alpha-1 antitrypsin deficiency, suggest a potential shift towards a more positive outlook, with the market now focusing on the translation of its differentiated RNAi and RNA editing capabilities into meaningful clinical outcomes and potential accelerated approval pathways.
- Subsidiaries On Linked In*
- {"subsidiaries":[]}
- Customer Sectors & Example Clients
- Wave Life Sciences primarily operates within the Biotechnology and Pharmaceuticals sectors. Their ultimate 'customers' are patients suffering from various genetic and metabolic diseases, including obesity, Alpha-1 antitrypsin deficiency (AATD), PNPLA3 I148M liver disease, and Duchenne muscular dystrophy (DMD). Their direct clients in terms of partnerships and collaborations include large pharmaceutical companies such as GlaxoSmithKline (GSK). They previously collaborated with Takeda Pharmaceutical Company Limited and Pfizer Inc.
- New Customers / Segments They'Re Targeting
- Wave Life Sciences is targeting new patient populations and market segments with its pipeline. For WVE-007 in obesity, they are evaluating it in a Phase IIa population with higher BMI and comorbidities, including those with and without type 2 diabetes, to demonstrate its potential in obesity and unlock other cardiometabolic indications like MASH and type 2 diabetes. They are also exploring combination therapy with incretins and maintenance therapy for patients discontinuing GLP-1s. For WVE-006, they are focused on the approximately 200,000 individuals in the U.S. and Europe living with homozygous ZZ AATD. With WVE-008, they aim to address PNPLA3 liver disease, targeting an estimated 9 million homozygous PNPLA3 I148M carriers across the U.S. and Europe.
- Supply Chain And Sourcing Geographies
- The company's supply chain and sourcing geographies are not specifically detailed in the provided information. As a clinical-stage biotechnology company, its supply chain likely involves specialized contract manufacturing organizations (CMOs) for oligonucleotide synthesis and drug product formulation. Specific locations for these activities are not disclosed.
- Sales Geographies And Expansion Plans
- As a clinical-stage company, Wave Life Sciences does not currently have commercial products generating sales. However, its clinical trials for WVE-007 are active at multiple sites, including in the U.S. For WVE-006, the focus is on individuals in the U.S. and Europe living with homozygous ZZ AATD. The company expresses a long-term vision for global reach, particularly for its obesity program, aiming to address the 'global 1 billion individuals living with obesity'.
- How Key Themes May Help/Hurt
- Wave Life Sciences is positioned to benefit from the 'MedTech Long '25: Adv Bio Therapeutics & Regenerative Med' theme due to the FDA's pro-innovation stance, which is expediting conditional approvals and removing red tape, potentially accelerating the path-to-market for cutting-edge therapeutics like Wave's RNA editing programs. The rebound in biotech venture capital and funding normalization could also boost demand for discovery platforms and trial-linked services, supporting Wave's capital-intensive R&D. Furthermore, Wave's data-rich assets and platform capabilities could be strategically valuable to pharma and AI-enabled R&D models. However, the company could be hurt if cash burn and small-cap apathy persist, making it challenging to fund operations or gain investor attention. There's also a risk that FDA accelerants prove illusory, leading to delays in regulatory pathways, and that data-rich assets fail to monetize if execution falters or budgets tighten.
3 Main Long-Term Bull Details
- Differentiated RNAi and RNA Editing Platforms: Wave's proprietary PRISM platform, including its SpiNA siRNA designs and GalNAc AIMer RNA editing technology, demonstrates superior potency, durability, and specificity, translating into differentiated preclinical and clinical data for multiple programs. This platform provides a structural advantage for developing best-in-class genetic medicines.
- Unique Obesity Therapeutic Profile (WVE-007): WVE-007 offers a highly differentiated approach to obesity treatment by promoting significant fat loss (including visceral fat) while preserving or increasing lean muscle mass, with a durable, infrequent dosing regimen (once or twice a year). This profile addresses key limitations of current GLP-1 therapies (muscle loss, frequent dosing, tolerability issues) and could capture a substantial market share, including maintenance and add-on therapy segments.
- Leadership in RNA Editing for Genetic Diseases: Wave is a leader in RNA editing, particularly with WVE-006 for AATD and WVE-008 for PNPLA3 I148M liver disease. These programs target the root cause of severe genetic diseases, offering the potential for transformative, disease-modifying therapies with a favorable safety profile and potential for accelerated regulatory approval pathways, addressing significant unmet medical needs.
3 Main Long-Term Bear Details
- High Cash Burn and Funding Needs: Wave Life Sciences reported a net loss of $69.4 million for Q2 2026 and increased R&D and G&A expenses. While they have a cash runway into Q3 2028, the continued advancement of multiple clinical programs is capital-intensive, and future funding beyond this period, especially without substantial milestone payments or new partnerships, remains a significant risk.
- Intense Competition and Market Perception in Obesity: The obesity market is highly competitive, dominated by large pharmaceutical companies with established GLP-1 therapies. Communicating the nuanced benefits of WVE-007's body composition improvements (fat loss with muscle preservation) to a market heavily focused on total body weight loss, and differentiating from other emerging INHBE programs, could be challenging.
- Clinical Trial and Regulatory Risks: Despite promising early data, all clinical-stage programs carry inherent risks of failure in later-stage trials, unexpected adverse events, or challenges in meeting regulatory endpoints for approval. The success of WVE-006's accelerated approval pathway and the translation of WVE-007's Phase I data into robust Phase II/III outcomes are critical and not guaranteed.
- Competitors And Differentiation
- Wave Life Sciences faces competition across its pipeline. For WVE-007 in obesity, competitors include established GLP-1 therapies (e.g., semaglutide) and other emerging INHBE programs. Wave differentiates WVE-007 through its proprietary chemistry and SpiNA siRNA design, which enables robust and durable silencing supporting potential once or twice-yearly dosing. Crucially, WVE-007 drives fat loss (including visceral fat) without muscle loss, addressing a key limitation of current GLP-1s. For WVE-006 in AATD, competitors include current IV augmentation therapy, investigational DNA editing approaches (e.g., Beam Therapeutics), and AAT siRNA approaches. Wave's RNA editing approach aims to restore the dynamic AAT protein response, treating both lung and liver manifestations, with convenient, infrequent subcutaneous dosing, and produces only wild-type canonical M-AAT without bystander edited isoforms. For WVE-008 in PNPLA3 liver disease, silencing approaches have shown to potentially exacerbate the disease. Wave's RNA editing approach aims to *correct* the I148M variant and restore functional protein, reversing steatosis and fibrosis. Overall, Wave's competitive positioning is built on its proprietary PRISM platform, which combines multiple modalities (RNAi and RNA editing), chemistry innovation, and deep genetic insights to design best-in-class RNA medicines.
- Recent Performance & What The Market'S Focused On
- Wave Life Sciences reported Q2 2026 revenue of $2.3 million, a decrease from $8.7 million in the prior year quarter, primarily related to its collaboration agreement with GSK. The net loss for Q2 2026 was $69.4 million, compared to $50.5 million in the prior year quarter, driven by increased R&D and G&A expenses. The company ended the quarter with $490.6 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into Q3 2028. The market is currently focused on the progress of the WVE-007 program for obesity, particularly the ongoing Phase IIa enrollment and the initiation of combination and maintenance studies. Key attention is also on the upcoming FDA meeting for WVE-006 to discuss a potential accelerated approval pathway for AATD, and the advancement of WVE-008 for PNPLA3 liver disease. Investors are also monitoring the company's cash burn, the sustainability of its operations, and the potential for new partnerships for its Duchenne muscular dystrophy and Huntington's disease programs.
- Revenue Segments And Estimated Mix
- Collaboration Agreements — Mix: largest segment; Source: Q2 2026 earnings call, Q4 2025 earnings summary; Trend: Q2 2026 revenue of $2.3 million, down from $8.7 million in prior year quarter; Q4 2025 revenue decreased significantly due to Takeda collaboration termination, partially offset by GSK collaboration.
- Product Brands
- WVE-007
- WVE-006
- WVE-008
- WVE-N531
- WVE-003
- PRISM
- SpiNA
- AIMers
Bull / Bear DetailsWave Life Sciences presents a high-risk, high-reward investment as of August 29, 2026, driven by promising RNAi and RNA editing pipeline advancements for obesit
Thesis
Wave Life Sciences presents a high-risk, high-reward investment as of August 29, 2026, driven by promising RNAi and RNA editing pipeline advancements for obesity (WVE-007), AATD (WVE-006), and PNPLA3 liver disease (WVE-008). However, the recent voluntary deregistration of its ordinary shares introduces significant uncertainty regarding its public market status and future funding mechanisms, potentially overshadowing clinical progress and ongoing profitability challenges.
Bull case
WVE-007 demonstrates a highly differentiated profile for obesity, achieving substantial fat loss, particularly visceral fat, while crucially preserving muscle mass. Its durable Activin E suppression supports potential once or twice-yearly dosing, addressing key limitations of current GLP-1s and positioning it strongly for add-on and maintenance therapies, with Phase IIa underway and combination studies planned.
Wave's RNA editing platform is validated by WVE-006 for AATD, with an FDA meeting granted for accelerated approval discussions and 600mg data expected. The platform's ability to restore functional protein without bystander editing, along with WVE-008 advancing for PNPLA3 liver disease with a differentiated mechanism, highlights broad potential and addresses high unmet needs.
The company maintains a solid financial position with cash and equivalents expected to fund operations into Q3 2028, excluding potential future milestone payments. The ongoing GSK collaboration, which continues to progress, provides non-dilutive funding and validates Wave's proprietary PRISM platform, further supported by strong liquidity.
Bear case
Wave Life Sciences' recent voluntary deregistration of its ordinary shares with the SEC introduces significant uncertainty regarding its public market status, reporting obligations, and future access to capital. This move, coupled with continued high R&D spend and increasing net losses, raises concerns about long-term funding mechanisms and investor confidence, potentially impacting pipeline progression.
The obesity market is highly competitive, dominated by established GLP-1s and numerous emerging therapies. Despite WVE-007's differentiated body composition profile, convincing payers and prescribers to adopt a novel mechanism over widely recognized weight loss metrics, especially against aggressive marketing, remains a significant challenge, requiring superior long-term efficacy and safety.
All clinical-stage programs carry inherent risks of failure in later-stage trials or challenges in meeting regulatory endpoints. The decision to explore partnerships for the DMD program (N531) before NDA filing, a shift from previous plans, introduces uncertainty and potential delays for that asset, reflecting evolving regulatory and commercial landscapes.
Bull / Bear Case
- Bear Case
- The bear case for Wave Life Sciences is primarily anchored by the significant uncertainty introduced by its recent voluntary deregistration of ordinary shares with the SEC, raising concerns about its public market status and future access to capital. This move, combined with continued high R&D expenses ($51.3M in Q2 2026) and increasing net losses ($69.4M in Q2 2026), highlights a substantial cash burn and long-term funding challenges. The obesity market is intensely competitive, and despite WVE-007's differentiated profile, convincing payers and prescribers against established GLP-1s remains a hurdle. Furthermore, all clinical programs carry inherent risks of failure, and the shift to explore partnerships for the DMD program (N531) signals evolving challenges for that asset. The stock's underperformance post-earnings reflects market skepticism.
- Bull Case
- Wave Life Sciences presents a compelling bull case driven by its highly differentiated RNAi and RNA editing pipeline, particularly WVE-007 for obesity, WVE-006 for AATD, and WVE-008 for PNPLA3 liver disease. WVE-007's unique ability to induce substantial fat loss while preserving muscle, with potential once or twice-yearly dosing, addresses key limitations of current obesity therapies and positions it strongly for add-on and maintenance markets. The RNA editing platform is validated by WVE-006, which has an FDA meeting granted for accelerated approval discussions, and WVE-008, advancing for a high unmet need in liver disease with a superior mechanism over silencing approaches. The company also maintains a solid cash runway into Q3 2028, supported by the ongoing GSK collaboration, providing crucial non-dilutive funding for pipeline advancement.
- More Compelling & Why
- Bear. Despite a negative Enterprise Value, which often signals undervaluation, the market's continued underperformance of the stock post-earnings, combined with the fundamental uncertainty from the voluntary deregistration, makes the bear case more compelling. The deregistration significantly impacts investor confidence, liquidity, and future funding mechanisms, overshadowing pipeline potential. My view would flip to bullish with a clear, positive resolution on the company's public market status and future capital strategy, alongside compelling, statistically significant Phase IIa data for WVE-007 demonstrating superior efficacy and safety.
Key Factors
| Key Factor | Why It Matters | What To Watch | What It Signals | Where/How To Track | Free Alt Data | Paid Alt Data |
|---|---|---|---|---|---|---|
| WVE-007 Phase IIa INLIGHT Trial First Key Assessments Data | This data will provide the first clinical insights into WVE-007's efficacy in a target patient population with higher BMI and comorbidities, which is crucial for validating its potential in obesity and broader cardiometabolic indications. Positive results could significantly de-risk the program and attract further investment. | Investors should watch for the announcement of results from the first key assessments at Day 85 of the Phase IIa INLIGHT trial. Key metrics include body weight reduction (aiming for 5% vs. placebo), visceral fat reduction, muscle preservation, and improvements in cardiometabolic biomarkers such as liver fat (MRI-PDFF), HbA1c, and lipid levels. | Bullish if: The data demonstrates clinically meaningful fat loss (especially visceral fat) with muscle preservation, achieving or exceeding a 5% weight loss, and showing positive trends in cardiometabolic biomarkers. Bearish if: The data shows insufficient fat loss, significant muscle loss, or a lack of improvement in cardiometabolic markers, particularly if it underperforms against the 5% weight loss threshold. | Company press releases, SEC filings (e.g., Form 8-K), and investor conference calls. The timing for this data release is not yet specified beyond 'once we have a cadence for when we can expect that we don't have to provide multiple updates on guidance, we'll have a good sense of patients and timing, and we'll provide that updated guidance as soon as we have a sense of the enrollment' (transcript). | ClinicalTrials.gov (NCT06842186) for study status updates. Industry news outlets (e.g., BioSpace, Fierce Biotech) for early reporting. | EvaluatePharma: Clinical trial progression and analyst consensus updates. BioCentury: Pipeline analysis and competitive landscape. |
| FDA Meeting Outcome for WVE-006 Accelerated Approval Pathway | The outcome of this meeting will define the regulatory pathway for WVE-006 in AATD, potentially accelerating its path to market. A clear and favorable path to accelerated approval would significantly de-risk the program and enhance its commercial potential. | Specific feedback from the FDA regarding accepted biomarkers (M-AAT or total AAT), confirmatory trial requirements, and overall alignment on a biomarker-driven accelerated approval pathway. The meeting is scheduled for the 'end of summer 2026'. | Bullish if: The FDA provides clear alignment on a biomarker-based accelerated approval pathway with manageable confirmatory trial requirements, potentially allowing for an interim analysis for accelerated approval. Bearish if: Significant hurdles or disagreements on the proposed pathway, requiring substantial additional studies or delays, or if the FDA does not grant an accelerated approval pathway. | Company press releases, SEC filings (e.g., Form 8-K), and investor conference calls following the 'end of summer 2026' meeting. | FDA website for guidance documents or meeting minutes (if publicly released). Industry news outlets for immediate reporting. | AdisInsight: Regulatory intelligence and approval timelines. GlobalData: Pharma intelligence and regulatory updates. |
| Initiation of WVE-007 Combination and Maintenance Phase II Trials | These new trials will explore critical commercial opportunities for WVE-007 beyond monotherapy, potentially deepening weight loss in combination with incretins and addressing the significant challenge of weight regain post-GLP-1 cessation. This expands the market potential and differentiation of WVE-007. | Announcement of the initiation of Phase II clinical studies for WVE-007 in combination with incretins and as a post-incretin maintenance therapy. These trials are on track to initiate in the second half of 2026. | Bullish if: Both combination and maintenance trials are initiated on schedule in the second half of 2026, demonstrating rapid advancement and strategic expansion of the WVE-007 program. Bearish if: There are delays in initiating these trials, indicating potential challenges in trial design, patient recruitment, or resource allocation. | Company press releases and SEC filings (e.g., Form 8-K) in the second half of 2026. | ClinicalTrials.gov for new study registrations. Industry news outlets for reporting on trial initiations. | TrialScope: Clinical trial database and intelligence. Phesi: Clinical development analytics. |
| WVE-008 Clinical Trial Application (CTA) Filing | The CTA filing for WVE-008 represents the advancement of Wave's second RNA editing candidate into clinical development, expanding their pipeline in liver disease. This milestone validates the broader potential of their RNA editing platform and addresses a high unmet need in PNPLA3 liver disease. | Announcement of the CTA filing for WVE-008. The filing is on track for the second half of 2026. | Bullish if: The CTA is filed on track in the second half of 2026, indicating smooth progress of the program into the clinic. Bearish if: There are unexpected delays in the CTA filing, suggesting potential preclinical or regulatory hurdles. | Company press releases and SEC filings (e.g., Form 8-K) in the second half of 2026. | ClinicalTrials.gov for new study registrations once the CTA is approved and the trial is initiated. Industry news outlets for reporting on CTA submissions. | GlobalData: Clinical trial intelligence and pipeline tracking. AdisInsight: Drug development milestones. |
| WVE-006 RestorAATion-2 Clinical Trial Data Update (600mg Monthly Dosing Cohort) | This data will provide crucial information on the efficacy and safety of WVE-006 at its highest dose, helping to inform the optimal dose regimen for future registrational studies. Strong data could further differentiate WVE-006 and solidify its 'MZ-like phenotype' claims. | Key metrics include basal M-AAT protein levels (at or above 11 micromolar), circulating M-AAT protein above the 50% heterozygous MZ threshold, corresponding decreases in mutant Z-AAT protein (e.g., 70% reduction seen with 200mg biweekly and 400mg monthly), and sustained restoration of the physiologic response to acute inflammatory events. Data is expected in the second half of 2026. | Bullish if: The 600mg monthly dosing cohort demonstrates sustained or improved M-AAT protein levels, continued robust reduction in Z-AAT, and a strong, durable acute phase response, further supporting a convenient, infrequent subcutaneous dosing. Bearish if: Protein levels decline, Z-AAT reduction is insufficient, or the acute phase response is weakened, suggesting a potential 'efficacy ceiling' at higher doses. | Company press releases, SEC filings (e.g., Form 8-K), and investor conference calls in the second half of 2026. | Industry news outlets (e.g., BioSpace, Fierce Biotech) for immediate reporting. | EvaluatePharma: Clinical trial results and competitive analysis. BioCentury: Pipeline analysis and expert commentary. |
Key Reported Metrics, Reratings Triggers & ResultsThis metric shows the company's investment in advancing its pipeline, particularly key clinical programs like WVE-007 and RNA editing candidates. Sustained, eff
Upcoming print · 2026-11-09
| Key reported metrics | ||
|---|---|---|
| Metric | Last period | Why it matters |
| Research and Development Expenses | $51.3 million (17.93% y/y growth) | This metric shows the company's investment in advancing its pipeline, particularly key clinical programs like WVE-007 and RNA editing candidates. Sustained, efficient investment is critical for future catalysts. |
| Net Loss | Net loss of $69.4 million (increased 37.43% y/y) | Reflects the company's cash burn and overall financial health. A growing net loss impacts the cash runway and highlights the need for successful clinical milestones or additional funding. |
| Total Revenue | $2.3 million (-73.56% y/y growth) | For a clinical-stage biotech, revenue primarily from collaborations indicates external validation and non-dilutive funding, crucial for pipeline advancement. A significant decline signals reliance on specific partnership milestones. |
Last reported · 2026-07-30
| Key reported metrics | Rerating thresholds | Earnings results | ||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date | Actual reported | Hit target? | Notes |
| Total Revenue | -79.45% | Exceeding this revenue threshold would signal that Wave Life Sciences is effectively managing its collaboration income, particularly from the GSK partnership, and mitigating the impact of the Takeda termination. It would demonstrate financial resilience and validate the company's ability to generate non-dilutive funding, which is critical for advancing its pipeline (WVE-006, WVE-008) and offsetting recent setbacks in the obesity program. This would help to alleviate investor concerns about cash burn and provide a clearer path to sustainable operations, supporting a positive rerating. | Total Revenue for Q1 2026 needs to exceed analyst consensus estimates of approximately $8.34 million to $8.45 million by at least 10-20%, meaning reported revenue in the range of $9.17 million to $10.14 million or higher. Additionally, positive guidance on future collaboration revenue or new partnership announcements would be crucial for a higher rerating. | Exceeding this revenue threshold would signal that Wave Life Sciences is effectively managing its collaboration income, particularly from the GSK partnership, and mitigating the impact of the Takeda termination. It would demonstrate financial resilience and validate the company's ability to generate non-dilutive funding, which is critical for advancing its pipeline (WVE-006, WVE-008) and offsetting recent setbacks in the obesity program. This would help to alleviate investor concerns about cash burn and provide a clearer path to sustainable operations, supporting a positive rerating. | $2.3 million (-73.56% y/y growth) | No | The rerating trigger was set for Q1 2026 revenue. The company reported Q2 2026 revenue of $2.3 million, a significant decrease of 73.56% year-over-year from $8.7 million in the prior year quarter. This figure is substantially below the Q1 2026 target range, indicating a miss. The decline in revenue was attributed to the ongoing GSK collaboration. The stock underperformed post-earnings, suggesting the market found the news in line with expectations or desired stronger catalysts. | |
| Net Loss | -281.23% | A smaller-than-expected net loss per share would signal improved operational efficiency and a more controlled cash burn than anticipated, especially following recent clinical setbacks. This reinforces the company's strong cash runway into Q3 2028 and its ability to fund critical pipeline programs, which are key drivers for long-term valuation and investor confidence. | Wave Life Sciences needs to report a Net Loss per share (EPS) of less than -$0.32 for Q1 2026, which would beat the current analyst consensus estimate of -$0.32 to -$0.34. A significant beat, such as an EPS loss of -$0.25 or better, would likely drive a higher rerating. | A smaller-than-expected net loss per share would signal improved operational efficiency and a more controlled cash burn than anticipated, especially following recent clinical setbacks. This reinforces the company's strong cash runway into Q3 2028 and its ability to fund critical pipeline programs, which are key drivers for long-term valuation and investor confidence. | Net loss of $69.4 million (increased 37.43% y/y) | No | The rerating trigger was for Q1 2026 EPS to be less than -$0.32, implying a smaller net loss. For Q2 2026, the company reported a net loss of $69.4 million, which is an increase of 37.43% compared to a net loss of $50.5 million in the prior year quarter. This represents a larger loss, missing the intent of the rerating trigger. The increased net loss primarily reflects higher research and development and general and administrative expenses. | |
| Research and Development Expenses | 18.39% | This threshold signals that Wave Life Sciences is effectively balancing pipeline acceleration with financial prudence. Achieving key clinical and regulatory milestones with controlled R&D expense growth would validate the investment thesis by demonstrating the productivity of their PRISM platform, extending their cash runway, and reducing future dilution risk, thereby enhancing competitive positioning and driving a positive rerating. | For a rerating higher, Wave Life Sciences needs to demonstrate efficient management of its R&D investments. This means maintaining year-over-year R&D expense growth at or below the Q4 2025 rate of 18.39% for Q1 2026, while simultaneously delivering strong positive clinical data for WVE-007 (including Phase 2a initiation and updates on 6-month 240mg and 3-month 400mg data) and WVE-006 (400mg multi-dose data and favorable regulatory feedback by mid-2026). | This threshold signals that Wave Life Sciences is effectively balancing pipeline acceleration with financial prudence. Achieving key clinical and regulatory milestones with controlled R&D expense growth would validate the investment thesis by demonstrating the productivity of their PRISM platform, extending their cash runway, and reducing future dilution risk, thereby enhancing competitive positioning and driving a positive rerating. | $51.3 million (17.93% y/y growth) | Partially | Research and development expenses for Q2 2026 were $51.3 million, representing a 17.93% year-over-year increase from $43.5 million in Q2 2025. This growth rate is slightly below the 18.39% threshold specified in the rerating trigger. Additionally, the company confirmed that the Phase IIa portion of the INLIGHT trial for WVE-007 is underway, and an FDA meeting for WVE-006 regarding a potential accelerated approval pathway is scheduled for the end of summer. While the specific 400mg multi-dose data for WVE-006 wasn't a new highlight in this Q2 call, the overall clinical progress and R&D expense management align partially with the rerating criteria. | |
Key QuestionsWill the initial data from the WVE-007 Phase IIa INLIGHT trial, specifically the first key assessments at Day 85, demonstrate clinically meaningful fat loss and
Will the initial data from the WVE-007 Phase IIa INLIGHT trial, specifically the first key assessments at Day 85, demonstrate clinically meaningful fat loss and cardiometabolic improvements in higher BMI patients, meeting the 5% weight loss threshold?
- Question 2
Will Wave Life Sciences receive clear and favorable guidance from the FDA regarding a biomarker-driven accelerated approval pathway for WVE-006 in AATD following their scheduled meeting at the end of summer?
- Question 3
Can Wave Life Sciences successfully initiate the planned WVE-007 combination and maintenance Phase II trials and file the WVE-008 CTA on schedule in the second half of 2026, demonstrating efficient pipeline execution amidst increasing R&D expenses and declining revenue?
Earnings Transcript Summary
· 2026Q2 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. Advancing WVE-007 for obesity: Management is focused on progressing WVE-007 through its Phase IIa trial in individuals with higher BMI and comorbidities, and initiating additional Phase II trials for combination and maintenance settings this year, aiming to redefine the obesity treatment landscape. 2. Accelerating WVE-006 for AATD towards accelerated approval: The company is actively engaging with the FDA to discuss a potential accelerated approval pathway for WVE-006, aiming to bring a new standard of care for Alpha-1 antitrypsin deficiency by treating both lung and liver manifestations. 3. Advancing the RNA editing pipeline with WVE-008: Management is focused on bringing its second RNA editing candidate, WVE-008 for PNPLA3 liver disease, into clinical development this year, addressing a high unmet need with an approach that restores functional protein. | Call Takeaway & ToneThe overall takeaway of the call was that Wave Life Sciences is making significant progress across its pipeline, particularly with WVE-007 in obesity, WVE-006 in AATD, and WVE-008 in liver disease. Management highlighted the differentiation of their proprietary chemistry and RNA editing platform, and their strategic focus on advancing these programs through clinical development and regulatory engagement. The tone of the call was confident and optimistic, emphasizing the potential for these candidates to redefine treatment landscapes and unlock significant value for patients. | Prior Quarter'S Y/Y Growth By SegmentFor the first quarter of 2026, revenue was $38.2 million, compared to $9.2 million in the prior year quarter, representing a year-over-year increase of approximately 315.22%. This revenue was largely tied to recognizing revenue from regaining full rights to WVE-006 and continued progress under its collaboration with GSK. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. WVE-007's Phase IIa goals and expansion into cardiometabolic indications: Analysts inquired about the specific metrics and magnitude of improvement needed in the Phase IIa INLIGHT trial to support expansion into MASH or type 2 diabetes. Management responded that the Phase IIa is designed to elicit a 5% weight loss for regulatory thresholds, but also to evaluate a broader cardiometabolic profile, including MRI-PDFF for liver fat, HbA1c, and lipid levels, in addition to body composition (visceral fat, total fat, muscle retention) to unlock opportunities in MASH and type 2 diabetes. 2. WVE-006's FDA meeting for accelerated approval: Analysts sought clarification on whether the upcoming FDA meeting for WVE-006 would be the first feedback on an accelerated approval pathway. Management confirmed it would be the first meeting and expressed excitement that the FDA granted a face-to-face discussion, aiming to get alignment on a biomarker-driven pathway and explore efficient study designs for both accelerated and full approval. 3. Confidence in WVE-007's BMI improvement with monotherapy and differentiation of WVE-008: Analysts questioned the confidence in WVE-007 showing BMI improvement with monotherapy, given human genetic data. Management responded by highlighting the correlation between the Activin E ligand and BMI, the expectation of greater effects in higher BMI populations, and observed total body fat reduction in Phase I. Regarding WVE-008, analysts asked how RNA editing would be superior to siRNA silencing for PNPLA3. Management emphasized that RNA editing restores functional protein, addressing inflammation and fibrosis, unlike silencing approaches which have shown potential worsening in liver disease. | Revenue SegmentsRevenue for the second quarter of 2026 was $2.3 million, compared to $8.7 million in the prior year quarter, representing a year-over-year decrease of approximately 73.56%. This revenue relates to the company's ongoing collaboration agreement with GSK. |
· 2025Q4 Earnings Call
| 3 Things Management Is Most Focused On | Call Takeaway & Tone | Prior Quarter'S Y/Y Growth By Segment | 3 Things Analysts Most Pressed On (And Mgmt Responses) | Revenue Segments |
|---|---|---|---|---|
| 3 Things Management Is Most Focused On1. **Accelerating development of WVE-007 for obesity:** Management is prioritizing the advancement of their WVE-007 and INHBE GalNAc siRNA program, emphasizing its potential to reduce fat while preserving muscle, a differentiated profile compared to existing GLP-1s. They plan to initiate the Phase IIa multi-dose portion of the INLIGHT study in the first half of 2026 and new clinical trials evaluating WVE-007 as an add-on to incretins and for post-incretin maintenance therapy in 2026. 2. **Rapidly advancing the RNA editing portfolio:** This includes WVE-006 for Alpha-1 Antitrypsin Deficiency (AATD), with regulatory feedback on a potential accelerated approval pathway expected in mid-2026, and WVE-008 for homozygous PNPLA3 I148M liver disease, with a CTA submission on track for 2026. 3. **Progressing the Duchenne Muscular Dystrophy (DMD) program and GSK collaboration:** Management is on track to submit an NDA in 2026 for accelerated approval of N531 for DMD. The ongoing research collaboration with GSK is also a focus, with a fourth program selected and an associated milestone payment received in the first quarter, highlighting potential for future milestone payments. | Call Takeaway & ToneThe overall takeaway of the call was that Wave Life Sciences had a tremendous 2025, marked by positive clinical data for WVE-007 in obesity and WVE-006 in AATD, validating their RNAi and RNA editing platforms. The company is strategically focused on accelerating these key programs and advancing its broader RNA editing pipeline in 2026. Despite a significant year-over-year revenue decline in Q4 2025 due to the termination of the Takeda collaboration, the company emphasized the strong potential of its pipeline assets and the ongoing GSK collaboration. The tone of the call was generally positive and confident, with management expressing excitement about their clinical data, the differentiation of their programs, and their strategic focus for the upcoming year. | Prior Quarter'S Y/Y Growth By SegmentFor the third quarter of 2025, revenue was $7.6 million, compared to negative $7.7 million in the prior year quarter. This represents a substantial year-over-year increase and a turnaround from negative to positive revenue, primarily attributable to the timing of revenue recognized under the collaboration agreement with GSK. | 3 Things Analysts Most Pressed On (And Mgmt Responses)1. **AATD regulatory strategy and accelerated approval pathway:** Analysts inquired about Wave's regulatory strategy for WVE-006, particularly in comparison to a competitor's recent alignment with the FDA on a biomarker-based accelerated approval framework. Management responded that their strategy is closely aligned with a biomarker approach, focusing on M-AAT protein levels and restoring the physiologic response to inflammatory stress, and they anticipate receiving regulatory feedback by mid-2026 on a registrational pathway. 2. **WVE-007 (INHBE) data timelines and expectations for weight/fat loss:** Analysts pressed on the timing of upcoming data readouts for WVE-007, specifically the six-month data for the 240-milligram cohort and three-month data for the 400-milligram cohort, and internal targets for weight loss. Management confirmed that data is on track and will be presented this quarter, emphasizing that while weight loss is important, their primary focus is on improvements in body composition (fat reduction, muscle preservation) as a key driver of health outcomes, especially as they move into the Phase IIa study with higher BMI patients. 3. **Differentiation of WVE-007 and the activin E space dynamics:** Analysts questioned how WVE-007 differentiates from other activin E strategies and competitors, and whether the market can accommodate multiple players. Management asserted that Wave is well-positioned to be a leader in INHBE silencing due to their proprietary SpiNA siRNA design, which has demonstrated differentiated preclinical and clinical data (e.g., unprecedented Ago2 loading, sustained activin E reduction, fat loss without muscle loss). They believe the obesity space is large enough for multiple players but highlighted their unique profile and once-to-twice-a-year dosing as key differentiators. | Revenue SegmentsFor the fourth quarter of 2025, revenue was $17.2 million, a significant decrease from $83.7 million in the prior year quarter, representing a year-over-year decline of approximately 79.45%. This decrease was primarily attributed to revenue recognized upon the termination of the Takeda collaboration in October 2024, partially offset by increases in revenue recognized under the collaboration agreement with GSK. For the full year 2025, revenue was $42.7 million, down from $108.3 million in 2024, a year-over-year decrease of approximately 60.57%, driven by the same factors. |
Transcript Tidbits
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketWave Life Sciences is exploring WVE-007 in a Phase IIa population with higher BMI and comorbidities to unlock other cardiometabolic indications, including MASH and type 2 diabetes. They are also evaluating combination with incretin and maintenance therapy, which represents an entirely new commercial frontier for obesity. WVE-006 aims to treat both lung and liver manifestations of AATD for 200,000 individuals in the U.S. and Europe. WVE-008 for PNPLA3 liver disease targets 9 million individuals living with homozygous PNPLA3 I148M liver disease in the U.S. and Europe, an area of high unmet need. | About CompetitionWVE-007 is differentiated from incretin therapy by leading to substantial reductions in visceral and subcutaneous fat without muscle loss, addressing tolerability issues, treatment burden, or anhedonia associated with incretins. Its proprietary chemistry and SpiNA sRNA design offer dramatically improved silencing potency and durability compared to industry-leading sRNA designs. WVE-006 offers a differentiated value proposition over current IV augmentation standard of care (no impact on liver manifestations) and investigational DNA editing (safety concerns, payer challenges for one-time costly therapy, uncertain durability, bystander editing risk, editing in cancer-associated genes). WVE-008's RNA editing approach is presented as the only way to restore functional protein for PNPLA3 liver disease, as silencing approaches have shown to not address the disease and may actually exacerbate it, with recent clinical trials observing dose-dependent increases in liver enzymes with PNPLA3 silencing. | About The Broader IndustryThe broader industry is seeing a shift in obesity treatment, with WVE-007 aiming to redefine the treatment landscape by focusing on fat loss without muscle loss, addressing a key limitation of current weight loss therapies. There's an emerging focus on improving body composition (decreasing excess fat and preserving muscle) rather than just BMI. The FDA is showing openness to biomarker-driven accelerated approval pathways for genetic diseases, as evidenced by granting Wave's request for a meeting to discuss a potential accelerated approval pathway for WVE-006. | Where Things Are HeadedFor WVE-007, the Phase IIa trial in individuals with obesity is underway, and additional Phase II trials for incretin combination and post-incretin maintenance are rapidly working to advance later this year. WVE-006 is on track to meet with regulators at the end of summer to discuss a pathway to accelerated approval. WVE-008 is advancing toward the clinic with a CTA filing expected later this year. Wave Life Sciences plans to host its Annual Investor Day in the fall to shed more light on latest platform advancements and work on bifunctional modality. The company is exploring potential partnerships for HD and DMD (N531) given the evolving regulatory and commercial landscape. Wave expects its $490.6 million in cash, cash equivalents, and marketable securities to fund operations into Q3 2028, with potential milestone payments from GSK in H2 2026. | Updates On ThemeAdv | Broader Themes EmergingA broader theme emerging is the shift in obesity treatment focus from solely weight loss to improved body composition, specifically targeting visceral fat reduction while preserving muscle mass. Another theme is the increasing use of biomarker-driven accelerated approval pathways by regulatory bodies like the FDA for genetic and rare diseases. | Bullish-Leaning Quotes (Short)Over the past decade, we have built the most sophisticated and broadly enabled oligonucleotide platform in the industry. In the first half of 2026, we delivered multiple positive data sets across our RNAi and RNA editing pipeline. We're excited that instead of a written response, the FDA granted a face-to-face discussion on an accelerated approval pathway. We ended the second quarter with $490.6 million in cash, cash equivalents and marketable securities, which we expect to be sufficient to fund operations into Q3 2028. | Bearish-Leaning Quotes (Short)Our revenue for the second quarter of 2026 was $2.3 million compared to $8.7 million in the prior year quarter. Research and development expenses were $51.3 million in the second quarter of 2026 as compared to $43.5 million in the same period in 2025. Our G&A expenses were $24.8 million for the second quarter of 2026 as compared to $18 million for the prior year quarter. As a result, our net loss was $69.4 million for the second quarter of 2026 as compared to a net loss of $50.5 million in the prior year quarter. Given the evolving regulatory and commercial landscape in DMD, we are exploring potential partnerships in advance of filing an NDA for N531. |
| About Expanding Eligible Market | About Competition | About The Broader Industry | Where Things Are Headed | Updates On Theme | Broader Themes Emerging | Bullish-Leaning Quotes (Short) | Bearish-Leaning Quotes (Short) |
|---|---|---|---|---|---|---|---|
| About Expanding Eligible MarketWave Life Sciences is expanding its eligible market by targeting obesity with WVE-007, which aims to address the substantial need for better next-generation treatment options beyond GLP-1s, including as an add-on to incretins and for post-incretin maintenance therapy. The company also highlights the global market of 1 billion patients worldwide living with obesity. For Alpha-1 antitrypsin deficiency (AATD), WVE-006 targets approximately 200,000 individuals in the U.S. and Europe living with homozygous ZZ AATD, and the RNA editing approach opens up opportunities for liver indications in addition to lung manifestations. WVE-008 for PNPLA3 I148M liver disease targets an estimated 9 million homozygous PNPLA3 I148M carriers with liver disease across the U.S. and Europe, addressing not only MASH but a whole set of different liver diseases. | About CompetitionWave Life Sciences differentiates WVE-007 from GLP-1s by emphasizing its ability to achieve fat loss similar to semaglutide without associated muscle loss, and driving greater reductions in visceral fat. They note that GLP-1s require frequent dosing, have tolerability challenges, induce muscle loss, and result in high discontinuation rates and weight cycling. The company chose to target Activin E through INHBE silencing over its receptor ALK7 due to a more selective approach with lower risk of unintended consequences. Wave asserts that its proprietary SpiNA designs distinguish WVE-007 from other competitors, with preclinical data remaining differentiated. Regarding AATD, Wave's regulatory strategy aligns with a competitor's biomarker-based accelerated approval framework, but highlights its advantage of making only M-AAT protein without bystander edited proteins. Wave believes it is well-poised to be the leader for INHBE silencing, stating that its chemistry is highly differentiated and that other INHBE programs look remarkably similar. | About The Broader IndustryThe broader industry is seeing a shift in the obesity treatment paradigm, moving away from a sole focus on total body weight loss to a greater emphasis on improvements in body composition, specifically decreasing metabolically harmful fat tissue and preserving healthy functional muscle tissue. There is widespread recognition of the need for novel obesity mechanisms and therapeutics beyond incretins. In genetic medicines, the FDA is showing openness to biomarker-based accelerated approval pathways and 'plausible mechanism pathways' for diseases like AATD. The industry is also exploring RNA editing as a means to restore endogenous protein levels and physiologic responses, as seen with WVE-006 in AATD. | Where Things Are HeadedWave Life Sciences is strategically focused on accelerating the development of WVE-007 for obesity and rapidly advancing its RNA editing portfolio. For WVE-007, the company expects to announce six-month follow-up data from the 240-milligram single-dose cohort and three-month follow-up data from the 400-milligram single-dose cohort later this quarter. The Phase IIa multi-dose portion of the INLIGHT study, enrolling patients with higher BMI and comorbidities, is on track to initiate in the first half of this year. New clinical trials evaluating WVE-007 as an incretin add-on and post-incretin maintenance therapy are on track to initiate in 2026. For WVE-006 in AATD, regulatory feedback on a potential accelerated approval pathway is anticipated in mid-2026, with data from the 400-milligram multi-dose cohort expected this quarter and single/multi-dose data from the 600-milligram cohort in 2026. WVE-008 for PNPLA3 I148M liver disease is on track for CTA submission in 2026. An NDA for accelerated approval of N531 for DMD is on track for submission in 2026. The GSK collaboration continues to progress, with a fourth program selected and milestone payments expected in 2026 and beyond. The company expects its cash and cash equivalents to fund operations into the third quarter of 2028. | Updates On ThemeAdv | Broader Themes EmergingA broader theme emerging is the shift in focus for obesity treatment from solely weight loss to improving body composition (fat reduction, muscle preservation) for better health outcomes. Another theme is the increasing use of biomarker-driven accelerated approval pathways by regulatory bodies like the FDA for genetic and rare diseases, emphasizing 'plausible mechanism pathways'. | Bullish-Leaning Quotes (Short)2025 was a tremendous year for Wave, marked by positive clinical data sets in obesity and AATD. In our lowest therapeutic dose cohort just three months after a single dose of 007, we observed fat loss similar to semaglutide without the associated muscle loss. We ended the year with $602.1 million in cash and cash equivalents, which we expect will be sufficient to fund the operations into the third quarter of 2028. Wave is well poised to be the leader for INHBE silencing. | Bearish-Leaning Quotes (Short)The quarter-over-quarter and year-over-year decreases were attributable to revenue recognized upon the termination of the Takeda collaboration in October 2024. Net loss for the full year of 2025 was $204.4 million as compared to net loss of $97 million in 2024. |
Notes
| Date | Comment | Comment Type | Comment Sentiment | Link | Price Reaction |
|---|---|---|---|---|---|
| 2026-02-26 | Wave Life Sciences reported positive WVE-007 obesity data, showing fat loss and muscle preservation, and advanced RNA editing programs (WVE-006, WVE-008). The company also highlighted a strong cash runway into Q3 2028. Despite these updates, the stock underperformed the SPY by over 3% post-earnings, suggesting the market perceived the news as largely in line with expectations or desired more significant catalysts. | Other | Neutral | -4.20% (vs SPY: -3.22%) | |
| 2026-07-30 | Wave Life Sciences' Q2 2026 earnings highlighted WVE-007's Phase IIa progress in obesity, WVE-006's FDA meeting for accelerated approval, and WVE-008's CTA filing. Despite positive clinical updates and a cash runway into Q3 2028, increased net loss and exploring DMD partnerships led to a -5.16% stock decline (t+2 days), underperforming the SPY, indicating market disappointment or perceived lack of new significant catalysts. | Earnings Transcript | Negative | -5.16% (vs SPY: -9.03%) |
Upcoming Events
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type |
|---|---|---|---|---|---|---|---|---|
| WVE_fecf2e7a | after that meeting (meeting 'end of summer') | 2026-09-01 | 2026-10-31 | Receipt of FDA feedback following a meeting to discuss a potential accelerated approval pathway for WVE-006 in Alpha-1 Antitrypsin Deficiency. | This feedback is critical for defining the registrational study design and timeline for WVE-006, potentially accelerating its path to market and validating Wave's RNA editing platform. | Ticker | 2026-07-30 | earnings_transcript |
| WVE_3a372b71 | second half of this year | 2026-09-01 | 2026-12-31 | Release of clinical data from the 600-milligram monthly dosing cohort of the RestorAATion-2 trial for WVE-006 in Alpha-1 Antitrypsin Deficiency. | This data will help inform the optimal dose regimen for WVE-006 and provide further evidence of its therapeutic profile, which is crucial for its registrational plans and potential accelerated approval. | Ticker | 2026-07-30 | earnings_transcript |
| WVE_a34877eb | later this year | 2026-09-01 | 2026-12-31 | Clinical Trial Application (CTA) submission for WVE-008 for the treatment of homozygous PNPLA3 I148M liver disease. | This submission marks the advancement of Wave's second RNA editing candidate into clinical development, expanding its pipeline and validating the platform's broader applicability in addressing high unmet needs in liver diseases. | Ticker | 2026-07-30 | earnings_transcript |
| WVE_29e0b824 | later this year | 2026-09-01 | 2026-12-31 | Initiation of additional Phase II clinical trials for WVE-007, evaluating its potential in combination with incretins and as a post-incretin maintenance therapy for obesity. | These trials expand the development program for WVE-007 into new, commercially significant market segments, potentially differentiating it from existing obesity treatments and enhancing its market opportunity. | Ticker | 2026-07-30 | earnings_transcript |
| WVE_8fe27c5d | this year | 2026-09-01 | 2026-12-31 | Release of additional Phase I INLIGHT clinical data for WVE-007, specifically including results from the 600-milligram cohort. | This data will provide further insights into the durability and efficacy of WVE-007 at a higher dose, which could strengthen its competitive profile and inform future development strategies in obesity. | Ticker | 2026-07-30 | earnings_transcript |
| WVE_2167fb27 | in 2026 | 2026-01-01 | 2026-12-31 | Submission of a New Drug Application (NDA) for accelerated approval of N531 with a monthly dosing regimen for Duchenne Muscular Dystrophy (DMD). | An NDA submission would be a significant step towards commercialization for N531, potentially offering a new treatment option for DMD patients and generating revenue for Wave. | Ticker | 2026-02-26 | earnings_transcript |
| WVE_87860d6a | in 2026 | 2026-01-01 | 2026-12-31 | Initiation of new clinical trials evaluating WVE-007 as an incretin add-on and as a post-incretin maintenance therapy. | These trials could position WVE-007 as a complementary or alternative therapy to GLP-1s, addressing unmet needs in tolerability, muscle preservation, and long-term weight management, potentially expanding its commercial potential. | Ticker | 2026-02-26 | earnings_transcript |
| WVE_588bde35 | in 2026 and beyond | 2026-01-01 | 2026-12-31 | Receipt of additional milestone payments from the research collaboration with GSK as programs advance. | These milestone payments provide non-dilutive funding, validate Wave's PRISM platform, and contribute to the company's cash runway, supporting its R&D efforts. | Ticker | 2026-02-26 | earnings_transcript |